AC Immune SA

AC Immune SA is a biotechnology company focused on developing precision medicine to treat neurodegenerative diseases, including Alzheimer’s and Parkinson’s, by leveraging advanced therapeutic platforms and techniques. Founded in 2003 and headquartered in Lausanne, Switzerland, AC Immune SA specializes in innovative therapies for neurodegenerative diseases. The company has undergone significant funding rounds, with its most recent PIPE round raising USD 50. 00 mn led by BVF Partners.

The CEO, Andrea Pfeifer, has guided the firm since its inception, contributing to its focus on addressing the challenges posed by proteinopathies associated with neurodegeneration. AC Immune has raised a total of USD 50. 00 mn to date, with eight completed deals, the latest being on September 22, 2016. AC Immune SA specializes in precision medicine aimed at treating neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and certain rare indications.

The company's core product offerings include a diverse pipeline of clinical and preclinical candidates, which encompass active immunotherapies, antibodies, small molecule drugs, and diagnostic agents. These products are designed to target specific proteinopathies associated with neurodegeneration, with a focus on detecting and clearing misfolded proteins that contribute to these conditions. By employing advanced technology platforms like Morphomer® and Supraantigen®, AC Immune aims to develop innovative therapies tailored to the unique biological profiles of patients. The company serves a global client base that includes pharmaceutical partners such as Janssen Pharmaceuticals, Takeda, and Eli Lilly and Co.

, targeting markets in North America, Europe, and Asia where there is a significant prevalence of neurodegenerative diseases. In 2023, AC Immune reported revenue of USD 16. 48 mn, while also experiencing an EBITDA loss of USD 57. 25 mn for the same year.

The company’s revenue model largely revolves around partnerships and collaborations with major pharmaceutical companies, which may involve licensing agreements and joint ventures for the development of therapeutics and diagnostics. These collaborations facilitate the sharing of resources and expertise, allowing AC Immune to advance its product offerings while minimizing the financial burden associated with independent development. Transactions typically encompass upfront payments, milestone payments tied to specific development achievements, and royalties on product sales once they reach the market. The company's flagship products are expected to follow a structured pricing model aligned with industry standards for biopharmaceuticals, protecting its revenue streams while managing development costs.

AC Immune plans to leverage its recent funding to enhance its product pipeline and expand its market reach. The company is focused on developing new products targeting neurodegenerative diseases, with particular emphasis on innovative therapies. The funding raised in September 2016 will be utilized strategically to support ongoing clinical trials and the advancement of its proprietary platforms. AC Immune aims to expand into North America, Europe, and Asia, where neurodegenerative diseases are prevalent, further solidifying its market presence.

With a clear strategy for product launches and market expansion, AC Immune is poised for continued growth.